Patents by Inventor Yuhong Zhou
Yuhong Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951173Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.Type: GrantFiled: April 12, 2021Date of Patent: April 9, 2024Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.Inventors: Yuhong Zhou, Ziping Wei
-
Publication number: 20240075154Abstract: An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.Type: ApplicationFiled: November 19, 2021Publication date: March 7, 2024Inventors: Bing XIA, Yuhong ZHOU, Ziping WEI, Jianfeng YANG
-
Publication number: 20240009318Abstract: The present invention provides isolated antibodies that bind to the human EGFR protein, and ADCs of the antibodies. Pharmaceutical compositions including the antibodies and ADCs, and methods of treating cancer are also provided.Type: ApplicationFiled: November 19, 2021Publication date: January 11, 2024Inventors: Bing XIA, Yuhong ZHOU, Ziping WEI, Lixia CAO, Fangdun JIANG
-
Publication number: 20240002527Abstract: Isolated anti-human CD73 antibody includes two heavy chains each including a hinge region comprising an amino acid sequence of that allow site-specific conjugation of cytotoxic drugs. Each heavy chain can include a human CH1 domain located upstream of and connected to the hinge region. The CH1 domain comprising a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs containing the antibody conjugated with a cytotoxic drug are also provided. Pharmaceutical compositions including the antibody or the ADCs, and methods of treating cancer using the pharmaceutical compositions are also provided.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Inventors: Bing XIA, Cui FENG, Lixia GU, Chen LI, Yuhong ZHOU, Ziping WEI
-
Publication number: 20230414781Abstract: Isolated anti-human B7-H3 antibody includes two heavy chains including a hinge region comprising an amino acid sequence that allows site-specific conjugation of cytotoxic drugs. Each heavy chain includes a human CH1 domain located upstream of and connected to the hinge region. The CH1 domain comprises a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs containing the antibody conjugated with a cytotoxic drug are also provided. Pharmaceutical compositions including the antibody or the ADCs, and methods of treating cancer using the pharmaceutical compositions are also provided.Type: ApplicationFiled: November 19, 2021Publication date: December 28, 2023Inventors: Bing XIA, Hao KONG, Lixia CAO, Fangdun JIANG, Yuhong ZHOU, Ziping WEI
-
Publication number: 20220211693Abstract: A quinoline derivative used for soft tissue sarcoma combination therapy, relating to a use of the quinoline derivative in combination with a second therapeutic drug to treat soft tissue sarcoma, wherein the second therapeutic drug may be a chemotherapy drug, a small molecule targeted anti-tumour drug or an immunotherapy drug. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.Type: ApplicationFiled: May 11, 2020Publication date: July 7, 2022Inventors: Zhiming WANG, Shilong ZHANG, Rongyuan ZHUANG, Xi GUO, Yan WANG, Hua YANG, Weiqi LU, Yuhong ZHOU, Lei GAO
-
Publication number: 20210346510Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.Type: ApplicationFiled: April 12, 2021Publication date: November 11, 2021Inventors: Yuhong Zhou, Ziping Wei
-
Patent number: 10994021Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.Type: GrantFiled: April 29, 2020Date of Patent: May 4, 2021Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.Inventors: Yuhong Zhou, Ziping Wei
-
Patent number: 10710359Abstract: A screen printing device and a screen printing method are provided. The screen printing device includes a screen plate and an electrifying device, the screen plate includes a conductive mesh; and the electrifying device is electrically connected with the conductive mesh and configured to apply voltage to the conductive mesh. The screen printing method includes: adopting a printing head to rub against a screen plate to print ink onto a substrate for silk screen printing, wherein the screen plate includes a conductive mesh; and applying voltage with positive or negative polarity to the conductive mesh in the screen printing process.Type: GrantFiled: April 17, 2017Date of Patent: July 14, 2020Assignees: BOE TECHNOLOGY GROUP CO., LTD., CHENGDU BOE OPTOELECTRONICS TECHNOLOGY CO., LTD.Inventors: Kang Zhang, Yuhong Zhou, Duling Qin, Chengpeng Li, Qian Qu
-
Publication number: 20180244036Abstract: A screen printing device and a screen printing method are provided. The screen printing device includes a screen plate and an electrifying device, the screen plate includes a conductive mesh; and the electrifying device is electrically connected with the conductive mesh and configured to apply voltage to the conductive mesh. The screen printing method includes: adopting a printing head to rub against a screen plate to print ink onto a substrate for silk screen printing, wherein the screen plate includes a conductive mesh; and applying voltage with positive or negative polarity to the conductive mesh in the screen printing process.Type: ApplicationFiled: April 17, 2017Publication date: August 30, 2018Inventors: Kang ZHANG, Yuhong ZHOU, Duling QIN, Chengpeng LI, Qian QU
-
Patent number: 10053509Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: GrantFiled: October 17, 2016Date of Patent: August 21, 2018Assignee: Eisai, Inc.Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Publication number: 20170029509Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: ApplicationFiled: October 17, 2016Publication date: February 2, 2017Inventors: YUHONG ZHOU, BRIAN TOMKOWICZ, LUIGI GRASSO, NICHOLAS C. NICOLAIDES, PHILIP M. SASS
-
Patent number: 9505842Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: GrantFiled: October 8, 2014Date of Patent: November 29, 2016Assignee: Morphotek, Inc.Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 9083628Abstract: A network content service apparatus includes a set of compute elements adapted to perform a set of network services; and a switching fabric coupling compute elements in said set of compute elements. The set of network services includes firewall protection, Network Address Translation, Internet Protocol forwarding, bandwidth management, Secure Sockets Layer operations, Web caching, Web switching, and virtual private networking. Code operable on the compute elements enables the network services, and the compute elements are provided on blades which further include at least one input/output port.Type: GrantFiled: February 4, 2013Date of Patent: July 14, 2015Assignee: Juniper Networks, Inc.Inventors: Mark Bryers, Elango Ganesan, Frederick Gruner, David Hass, Robert Hathaway, Ramesh Panwar, Ricardo Ramirez, Abbas Rashid, Mark Vilas, Nazar Zaidi, Yen Lee, Chau Anh Ngoc Nguyen, John Phillips, Yuhong Zhou, Gregory G. Spurrier, Sankar Ramanoorthi, Michael Freed
-
Publication number: 20150079104Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: ApplicationFiled: October 8, 2014Publication date: March 19, 2015Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 8956832Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.Type: GrantFiled: July 2, 2013Date of Patent: February 17, 2015Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
-
Patent number: 8895000Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: GrantFiled: September 1, 2010Date of Patent: November 25, 2014Assignee: Morphotek, Inc.Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Publication number: 20130305396Abstract: Provided herein are rodents that express the human endosialin gene. In preferred embodiments, the rodent is a mouse. Preferably, the human endosialin gene is integrated into the native or endogenous endosialin gene locus. More preferably, the host rodent is null for the endogenous endosialin gene product. The human endosialin gene is preferably expressed in a similar development and disease response pattern as that of the native endosialin gene product in parental or wild type rodents. This feature makes these rodents useful for studying the effects of test agents to positively or negatively affect endosialin biology for therapeutic use. Use of human endosialin expressing rodents lacking native endosialin gene product (HUE rodents) is proposed as a strategy for developing agents that can positively or negatively affect the endosialin pathway and also serve as a screening tool to identify those agents that may be useful as human therapies.Type: ApplicationFiled: September 28, 2011Publication date: November 14, 2013Inventors: Luigi Grasso, Jian Min Lin, Yuhong Zhou, Brian E. Tomkowicz, Nicholas C. Nicolaides, Philip M. Sass
-
Publication number: 20130287691Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.Type: ApplicationFiled: July 2, 2013Publication date: October 31, 2013Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
-
Patent number: 8507657Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.Type: GrantFiled: August 23, 2012Date of Patent: August 13, 2013Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou